How AI is Transforming Clinical Trial Recruitment
The medical world is shifting underneath our feet.
To keep up with the rising demands of empowered patients, physicians and pharma businesses regularly test innovative treatments and medicines during rigorous clinical trials.
But one misguided move can trigger a domino effect, such as when the wrong patients are selected for a clinical trial.
Today’s infographic comes to us from Publicis Health, and it highlights why the current model of clinical trial recruitment urgently needs to change.
The Cost of Clinical Trials
Clinical trials help to determine if a new treatment, drug, or device is safe for the larger patient population.
Patients are at the heart of these clinical trials, and poor patient recruitment has dire consequences:
- 50% of sites enroll one or no patients in studies
- 85% of clinical trials fail to retain enough patients
- 80% of all clinical trials fail to finish on time
A single trial can cost anywhere from $44 million to $115 million. But here’s the kicker – according to a CenterWatch survey, delays can cost a trial between $600,000 and $8 million per day.
For these reasons, it’s crucial for pharma trial sponsors to find the right fit for clinical trials from the start.
A 360° View
The healthcare industry is moving towards a people-based marketing approach, to discover and engage the right patient one-on-one.
Advanced technology and connected patient data work in tandem with millions of real-time consumer behaviors, creating a rich and accurate profile of the perfect patient match.
The use of artificial intelligence, machine learning, and predictive analytics unearth further insights, weighting those patients with the behavioral tendencies most suited for the trial:
Actively reaching out to patients, wherever they are.
Continually refining media channels and messaging to further patient interest.
Nurturing relationships with patients, starting with the initial outreach.
Applying a people-based approach to patient recruitment has a myriad of benefits, many of which live on long after the original trial’s completion.
|Recruitment||- Accurate insight generation |
- Real time optimization
- Faster and improved quality
|- More efficient
- Increased conversion
- Reduced costs
|Engagement||- Behavioral-based messaging |
- Personalized trial participation experiences
|- Precise engagement at scale
- Drives patient adherence and retention during a trial
|Long-term benefits of data collected||- Develops patient profiles for future trials|
- Guides the planning of the patient demographic
- Informs drug launch activities
|- Accelerates recruitment and reduces start-up costs
- Speeds up commercialization of new drugs
- Supports disease awareness and educational campaigns
As clinical trials are successfully completed on time – allowing new drugs to reach the market faster than before – patients will benefit from easier access to groundbreaking treatments.
This is part five of a seven part series. Stay tuned by subscribing to Visual Capitalist for free, as we wrap up with the final two transformative forces shaping the future of healthcare.
Visualizing How COVID-19 Antiviral Pills and Vaccines Work at the Cellular Level
Despite tackling the same disease, vaccines and antiviral pills work differently to combat COVID-19. We visualize how they work in the body.
Current Strategies to Tackle COVID-19
Since the pandemic started in 2020, a number of therapies have been developed to combat COVID-19.
The leading options for preventing infection include social distancing, mask-wearing, and vaccination. They are still recommended during the upsurge of the coronavirus’s latest mutation, the Omicron variant.
But in December 2021, The United States Food and Drug Administration (USDA) granted Emergency Use Authorization to two experimental pills for the treatment of new COVID-19 cases.
These medications, one made by Pfizer and the other by Merck & Co., hope to contribute to the fight against the coronavirus and its variants. Alongside vaccinations, they may help to curb extreme cases of COVID-19 by reducing the need for hospitalization.
Despite tackling the same disease, vaccines and pills work differently:
|Taken by injection||Taken by mouth|
|Used for prevention||Used for treatment only|
|Create an enhanced immune system by stimulating antibody production||Disrupt the assembly of new viral particles|
How a Vaccine Helps Prevent COVID-19
The main purpose of a vaccine is to prewarn the body of a potential COVID-19 infection by creating antibodies that target and destroy the coronavirus.
In order to do this, the immune system needs an antigen.
It’s difficult to do this risk-free since all antigens exist directly on a virus. Luckily, vaccines safely expose antigens to our immune systems without the dangerous parts of the virus.
In the case of COVID-19, the coronavirus’s antigen is the spike protein that covers its outer surface. Vaccines inject antigen-building instructions* and use our own cellular machinery to build the coronavirus antigen from scratch.
When exposed to the spike protein, the immune system begins to assemble antigen-specific antibodies. These antibodies wait for the opportunity to attack the real spike protein when a coronavirus enters the body. Since antibodies decrease over time, booster immunizations help to maintain a strong line of defense.
*While different vaccine technologies exist, they all do a similar thing: introduce an antigen and build a stronger immune system.
How COVID Antiviral Pills Work
Antiviral pills, unlike vaccines, are not a preventative strategy. Instead, they treat an infected individual experiencing symptoms from the virus.
These medications disrupt specific processes in the viral assembly line to choke the virus’s ability to replicate.
The Mechanism of Molnupiravir
RNA-dependent RNA Polymerase (RdRp) is a cellular component that works similar to a photocopying machine for the virus’s genetic instructions. An infected host cell is forced to produce RdRp, which starts generating more copies of the virus’s RNA.
Molnupiravir, developed by Merck & Co., is a polymerase inhibitor. It inserts itself into the viral instructions that RdRp is copying, jumbling the contents. The RdRp then produces junk.
The Mechanism of Nirmatrelvir + Ritonavir
A replicating virus makes proteins necessary for its survival in a large, clumped mass called a polyprotein. A cellular component called a protease cuts a virus’s polyprotein into smaller, workable pieces.
Pfizer’s antiviral medication is a protease inhibitor made of two pills:
- The first pill, nirmatrelvir, stops protease from cutting viral products into smaller pieces.
- The second pill, ritonavir, protects nirmatrelvir from destruction by the body and allows it to keep working.
With a faulty polymerase or a large, unusable polyprotein, antiviral medications make it difficult for the coronavirus to replicate. If treated early enough, they can lessen the virus’s impact on the body.
The Future of COVID Antiviral Pills and Medications
Antiviral medications seem to have a bright future ahead of them.
COVID-19 antivirals are based on early research done on coronaviruses from the 2002-04 SARS-CoV and the 2012 MERS-CoV outbreaks. Current breakthroughs in this technology may pave the way for better pharmaceuticals in the future.
One half of Pfizer’s medication, ritonavir, currently treats many other viruses including HIV/AIDS.
Gilead Science is currently developing oral derivatives of remdesivir, another polymerase inhibitor currently only offered to inpatients in the United States.
More coronavirus antivirals are currently in the pipeline, offering a glimpse of control on the looming presence of COVID-19.
Author’s Note: The medical information in this article is an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. Please talk to your doctor before undergoing any treatment for COVID-19. If you become sick and believe you may have symptoms of COVID-19, please follow the CDC guidelines.
Mapped: The Most Common Illicit Drugs in the World
What are the most commonly used illicit drugs around the world?
Mapped: The Most Common Illicit Drugs in the World
Despite strict prohibitory laws around much of the world, many common illicit drugs still see widespread use.
Humans have a storied and complicated relationship with drugs. Defined as chemical substances that cause a change in our physiology or psychology, many drugs are taken medicinally or accepted culturally, like caffeine, nicotine, and alcohol.
But many drugs—including medicines and non-medicinal substances taken as drugs—are taken recreationally and can be abused. Each country and people have their own relationship to drugs, with some embracing the use of specific substances while others shun them outright.
What are the most common drugs that are considered generally illicit in different parts of the world? Today’s graphics use data from the UN’s World Drug Report 2021 to highlight the most prevalent drug used in each country.
What Types of Common Drugs Are Tracked?
The World Drug Report looks explicitly at the supply and demand of the international illegal drug market, not including commonly legal substances like caffeine and alcohol.
Drugs are grouped by class and type, with six main types of drugs found as the most prevalent drugs worldwide.
- Cannabis*: Drugs derived from cannabis, including hemp. This category includes marijuana (dried flowers), hashish (resin), and other for various other parts of the plant or derived oils.
- Cocaine: Drugs derived from the leaves of coca plants. Labeled as either cocaine salts for powder form or crack for cocaine processed with baking soda and water into rock form.
- Opioids: Includes opiates which are derived directly from the opium poppy plant, including morphine, codeine, and heroin, as well as synthetic alkaloids.
- Amphetamine-type Stimulants (ATS): Amphetamine and drugs derived from amphetamine, including meth (also known as speed), MDMA, and ecstasy.
- Sedatives and Tranquilizers: Includes other drugs whose main purpose is to reduce energy, excitement, or anxiety, as well as drugs used primarily to initiate or help with sleep (also called hypnotics).
- Solvents and Inhalants: Gases or chemicals that can cause intoxication but are not intended to be drugs, including fuels, glues, and other industrial substances.
The report also tracked the prevalence of hallucinogens—psychoactive drugs which strongly affect the mind and cause a “trip”—but no hallucinogens ranked as the most prevalent drug in any one country.
*Editor’s note: Recreational cannabis is legal in five countries, and some non-federal jurisdictions (i.e. states). However, in the context of this report, it was included because it is still widely illicit in most countries globally.
The Most Prevalent Drug in Each Country
According to the report, 275 million people used drugs worldwide in 2020. Between the ages of 15–64, around 5.5% of the global population used drugs at least once.
Many countries grouped different types of the same drug class together, and a few like Saudi Arabia and North Macedonia had multiple different drug types listed as the most prevalent.
But across the board, cannabis was the most commonly prevalent drug used in 107 listed countries and territories:
|Country or territory||Most Prevalent Drug(s)|
|Albania||Sedatives and tranquillizers (general)|
|Burkina Faso||Cannabis (general)|
|Central African Republic||Cannabis (herb)|
|Costa Rica||Cannabis (herb)|
|Côte d'Ivoire||Cannabis (herb)|
|Dominican Republic||Cocaine (powder)|
|El Salvador||Cannabis (herb)|
|Greece||Solvents and inhalants (general)|
|Hong Kong||Heroin, opium, opioids|
|Lithuania||Sedatives and tranquillizers (general)|
|New Zealand||Methamphetamine, solvent and inhalants|
|North Macedonia||Multiple types|
|Saudi Arabia||Multiple types|
|South Africa||Cannabis (general)|
|Sri Lanka||Cannabis (herb)|
|Syrian Arab Republic||Cannabis (hashish)|
|Trinidad and Tobago||Cocaine (crack)|
How prevalent is cannabis worldwide? 72 locations or more than two-thirds of those reporting listed cannabis as the most prevalent drug.
Unsurprisingly these include countries that have legalized recreational cannabis: Canada, Georgia, Mexico, South Africa, and Uruguay.
How Common Are Opioids and Other Drugs?
Though the global prevalence of cannabis is unsurprising, especially as it becomes legalized and accepted in more countries, other drugs also have strong footholds.
Opioids (14 locations) were the most prevalent drugs in the Middle-East, South and Central Asia, including in India and Iran. Notably, Afghanistan is the world’s largest producer of opium, supplying more than 90% of illicit heroin globally.
Amphetamine-type drugs (9 locations) were the third-most common drugs overall, mainly in East Asia. Methamphetamine was the reported most prevalent drug in China, South Korea, and Japan, while amphetamine was only the most common drug in Bangladesh.
However, it’s important to note that illicit drug usage is tough to track. Asian countries where cannabis is less frequently found (or reported) might understate its usage. At the same time, the opioid epidemic in the U.S. and Canada reflects high opioid usage in the West.
As some drugs become more widespread and others face a renewed “war,” the landscape is certain to shift over the next few years.
Money4 weeks ago
Visualizing the $94 Trillion World Economy in One Chart
Misc5 days ago
From Greek to Latin: Visualizing the Evolution of the Alphabet
Best of3 weeks ago
Our Top 21 Visualizations of 2021
Markets2 weeks ago
Prediction Consensus: What the Experts See Coming in 2022
Markets4 weeks ago
Mapped: Economic Freedom Around the World
Technology1 week ago
Companies Gone Public in 2021: Visualizing IPO Valuations
Misc2 weeks ago
Mapped: Top Trending Searches of 2021 in Every U.S. State
Green3 weeks ago
Mapped: 30 Years of Deforestation and Forest Growth, by Country